A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance (AMR) Solution

Area of Science:

• Infectious Diseases
• Drug Development
• Public Health Policy

Background:

• Antibiotics are vital for modern medicine and pandemic preparedness.
• Current funding models struggle to incentivize new antibiotic development due to profitability concerns.
• Existing initiatives like CARB-X, BARDA, and the AMR Action Fund show promise but do not fully address the access gap.

Purpose of the Study:

• To explore viable funding mechanisms for new antibiotic development.
• To identify strategies for securing global equitable access to essential antibiotics.
• To propose a framework prioritizing public health needs over commercial profitability.

Main Methods:

• Analysis of current preclinical and regulatory approval pipelines for antimicrobials.
• Evaluation of public and private funding initiatives in antibiotic research and development.
• Assessment of the economic and public health implications of different funding models.

Main Results:

• Commercial developers find new antibiotics insufficiently profitable, hindering the pipeline.
• Public funding and private investment are improving regulatory approvals but not market access.
• Nonprofit R&D organizations, supported by public funds, are identified as a viable alternative.

Conclusions:

• Public health need, not commercial profit, should drive antibiotic development.
• Improved prioritization and government oversight of public funding are crucial.
• Nonprofit organizations can bridge the gap, ensuring equitable global access to new antibiotics.